دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Ralph C Williams Jr and the world of rheumatology: a tribute from Sweden
Frank A Wollheim, G?ran Kronvall
doi : 10.1136/annrheumdis-2020-218852
(28 September, 2020)
Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: a viewpoint in 2020
Olivier Lortholary, Mario Fernandez-Ruiz, John W Baddley, Oriol Manuel, Xavier Mariette, Kevin L Winthrop
doi : 10.1136/annrheumdis-2020-217092
(22 September, 2020)
Biological therapies have improved the outcomes of several major inflammatory, autoimmune and also neoplastic disorders. Those directed towards cytokines or other soluble mediators, cell-surface molecules or receptors or various components of intracellular signalling pathways may be associated with the occurrence of infections whose diversity depends on the particular immune target.
Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study
Jose L Pablos, Mar?a Galindo, Loreto Carmona, Ana Lled?, Miriam Retuerto, Ricardo Blanco, Miguel A Gonzalez-Gay, David Martinez-Lopez, Isabel Castrej?n, José M Alvaro-Gracia, David Fern?ndez Fern?ndez, Antonio Mera-Varela, Sara Manrique-Arija, Natalia Mena V?zquez, Antonio Fernandez-Nebro
doi : 10.1136/annrheumdis-2020-218296
(12 August, 2020)
Objectives The impact of inflammatory rheumatic diseases on COVID-19 severity is poorly known. Here, we compare the outcomes of a cohort of patients with rheumatic diseases with a matched control cohort to identify potential risk factors for severe illness.
Two-year cost effectiveness between two gradual tapering strategies in rheumatoid arthritis: cost-utility analysis of the TARA trial
Elise van Mulligen, Angelique E Weel, Tjallingius Martijn Kuijper, N H A M Denissen, Andreas H Gerards, Mike H de Jager, Wai-Kwan Lam-Tse, J M Hazes, Annette van der Helm-van Mil, Pascal Hendrik Pieter de Jong, Jolanda J Luime
doi : 10.1136/annrheumdis-2020-217528
(9 September, 2020)
Objective The aim of the current study was to evaluate the 2-year cost-utility ratio between tapering conventional synthetic disease-modifying antirheumatic drugs (csDMARD) first followed by the tumour necrosis factor (TNF)-inhibitor, or vice versa, in patients with rheumatoid arthritis (RA).
Circulating microbial small RNAs are altered in patients with rheumatoid arthritis
Michelle J Ormseth, Qiong Wu, Shilin Zhao, Ryan M Allen, Joseph Solus, Quanhu Sheng, Yan Guo, Fei Ye, Marisol Ramirez-Solano, S Louis Bridges, Jeffrey R Curtis, Kasey Vickers, C Michael Stein
doi : 10.1136/annrheumdis-2020-217589
(21 September, 2020)
Objectives To determine if plasma microbial small RNAs (sRNAs) are altered in patients with rheumatoid arthritis (RA) compared with control subjects, associated with RA disease-related features, and altered by disease-modifying antirheumatic drugs (DMARDs).
Identification of new susceptibility loci associated with rheumatoid arthritis
Rui-Xue Leng, Dong-Sheng Di, Jing Ni, Xiao-Xiao Wu, Lin-Lin Zhang, Xu-Fan Wang, Rui-Shan Liu, Qian Huang, Yin-Guang Fan, Hai-Feng Pan, Bin Wang, Dong-Qing Ye
doi : 10.1136/annrheumdis-2020-217351
(31 August, 2020)
Objectives The present study aimed to discover novel susceptibility loci associated with risk of rheumatoid arthritis (RA).
Genomic risk scores for juvenile idiopathic arthritis and its subtypes
Rodrigo C?novas, Joanna Cobb, Marta Brozynska, John Bowes, Yun R Li, Samantha Louise Smith, Hakon Hakonarson, Wendy Thomson, Justine A Ellis, Gad Abraham, Jane E Munro, Michael Inouye
doi : 10.1136/annrheumdis-2020-217421
(4 September, 2020)
Objectives Juvenile idiopathic arthritis (JIA) is an autoimmune disease and a common cause of chronic disability in children. Diagnosis of JIA is based purely on clinical symptoms, which can be variable, leading to diagnosis and treatment delays. Despite JIA having substantial heritability, the construction of genomic risk scores (GRSs) to aid or expedite diagnosis has not been assessed. Here, we generate GRSs for JIA and its subtypes and evaluate their performance.
Blood-brain barrier leakage in systemic lupus erythematosus is associated with gray matter loss and cognitive impairment
Lyna Kamintsky, Steven D Beyea, John D Fisk, Javeria A Hashmi, Antonina Omisade, Cynthia Calkin, Tim Bardouille, Chris Bowen, Maher Quraan, Arnold Mitnitski, Kara Matheson, Alon Friedman, John G Hanly
doi : 10.1136/annrheumdis-2020-218004
(1 October, 2020)
Objectives To examine the association between blood-brain barrier (BBB) integrity, brain volume and cognitive dysfunction in adult patients with systemic lupus erythematosus (SLE).
Unique expansion of IL-21+ Tfh and Tph cells under control of ICOS identifies Sj?gren’s syndrome with ectopic germinal centres and MALT lymphoma
Elena Pontarini, William James Murray-Brown, Cristina Croia, Davide Lucchesi, James Conway, Felice Rivellese, Liliane Fossati-Jimack, Elisa Astorri, Edoardo Prediletto, Elisa Corsiero, Francesca Romana Delvecchio, Rachel Coleby, Eva Gelbhardt, Aurora Bono, Chiara Baldini, Ilaria Puxeddu, Piero Ruscitti, Roberto Giacomelli, Francesca Barone, Benjamin Fisher, Simon J Bowman, Serena Colafrancesco, Roberta Priori, Nurhan Sutcliffe, Stephen Challacombe, Gianluca Carlesso, Anwar Tappuni, Costantino Pitzalis, Michele Bombardieri
doi : 10.1136/annrheumdis-2020-217646
(22 September, 2020)
Objectives To explore the relevance of T-follicular-helper (Tfh) and pathogenic peripheral-helper T-cells (Tph) in promoting ectopic lymphoid structures (ELS) and B-cell mucosa-associated lymphoid tissue (MALT) lymphomas (MALT-L) in Sj?gren’s syndrome (SS) patients.
A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis
Yannick Allanore, Peter Wung, Christina Soubrane, Corinne Esperet, Frederic Marrache, Raphael Bejuit, Amel Lahmar, Dinesh Khanna, Christopher P Denton
doi : 10.1136/annrheumdis-2020-218447
(22 September, 2020)
Objectives Recent advances in systemic sclerosis (SSc) show that it involves a T-helper type-2-oriented immune response with interleukin (IL)-4 and IL-13. Romilkimab is an engineered, humanised, bispecific immunoglobulin-G4 antibody that binds and neutralises IL-4/IL-13 making it ideal for exploration in fibrosis.
Machine learning predicts stem cell transplant response in severe scleroderma
Jennifer M Franks, Viktor Martyanov, Yue Wang, Tammara A Wood, Ashley Pinckney, Leslie J Crofford, Lynette Keyes-Elstein, Daniel E Furst, Ellen Goldmuntz, Maureen D Mayes, Peter McSweeney, Richard A Nash, Keith M Sullivan, Michael L Whitfield
doi : 10.1136/annrheumdis-2020-217033
(15 September, 2020)
Objective The Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial demonstrated clinical benefit of haematopoietic stem cell transplant (HSCT) compared with cyclophosphamide (CYC). We mapped PBC (peripheral blood cell) samples from the SCOT clinical trial to scleroderma intrinsic subsets and tested the hypothesis that they predict long-term response to HSCT.
Risk of venous thromboembolism in knee, hip and hand osteoarthritis: a general population-based cohort study
Chao Zeng, Kim Bennell, Zidan Yang, Uyen-Sa D T Nguyen, Na Lu, Jie Wei, Guanghua Lei, Yuqing Zhang
doi : 10.1136/annrheumdis-2020-217782
(16 September, 2020)
Objectives Osteoarthritis is a leading cause of immobility and joint replacement, two strong risk factors for venous thromboembolism (VTE). We aimed to examine the relation of knee, hip and hand osteoarthritis to the risk of VTE and investigate joint replacement as a potential mediator.
Identification of the skeletal progenitor cells forming osteophytes in osteoarthritis
Anke J Roelofs, Karolina Kania, Alexandra J Rafipay, Meike Sambale, Stephanie T Kuwahara, Fraser L Collins, Joanna Smeeton, Maxwell A Serowoky, Lynn Rowley, Hui Wang, René Gronewold, Chrysa Kapeni, Sim?n Méndez-Ferrer, Christopher B Little, John F Bateman, Thomas Pap, Francesca V Mariani, Joanna Sherwood, J Gage Crump, Cosimo De Bari
doi : 10.1136/annrheumdis-2020-218350
(22 September, 2020)
Objectives Osteophytes are highly prevalent in osteoarthritis (OA) and are associated with pain and functional disability. These pathological outgrowths of cartilage and bone typically form at the junction of articular cartilage, periosteum and synovium. The aim of this study was to identify the cells forming osteophytes in OA.
TRIM24-RIP3 axis perturbation accelerates osteoarthritis pathogenesis
Jimin Jeon, Hyun-Jin Noh, Hyemi Lee, Han-Hee Park, Yu-Jin Ha, Seok Hee Park, Haeseung Lee, Seok-Jung Kim, Ho Chul Kang, Seong-il Eyun, Siyoung Yang, You-Sun Kim
doi : 10.1136/annrheumdis-2020-217904
(7 September, 2020)
Objectives Recently, necroptosis has attracted increasing attention in arthritis research; however, it remains unclear whether its regulation is involved in osteoarthritis (OA) pathogenesis. Since receptor-interacting protein kinase-3 (RIP3) plays a pivotal role in necroptosis and its dysregulation is involved in various pathological processes, we investigated the role of the RIP3 axis in OA pathogenesis.
Activation of acid-sensing ion channel 3 by lysophosphatidylcholine 16:0 mediates psychological stress-induced fibromyalgia-like pain
Chih-Hsien Hung, Cheng-Han Lee, Ming-Hsien Tsai, Chu-Huang Chen, Hsiu-Fen Lin, Chung-Yao Hsu, Chiou-Lian Lai, Chih-Cheng Chen
doi : 10.1136/annrheumdis-2020-218329
(9 September, 2020)
Objectives Fibromyalgia is commonly considered a stress-related chronic pain disorder, and daily stressors are known triggers. However, the relation between stress and pain development remains poorly defined by clinical approaches. Also, the aetiology remains largely unknown.
Impact of delayed diagnoses at the time of COVID-19: increased rate of preventable bilateral blindness in giant cell arteritis
Sara Monti, Paolo Delvino, Elisa Bellis, Alessandra Milanesi, Fabio Brandolino, Carlomaurizio Montecucco
doi : 10.1136/annrheumdis-2020-217915
(24 May, 2020)
Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases
Laura Nu?o, Marta Novella Navarro, Gema Bonilla, Karen Franco-G?mez, Pilar Aguado, Diana Peiteado, Irene Monjo, Carolina Tornero, Alejandro Villalba, Maria-Eugenia Miranda-Carus, Eugenio De Miguel, Patricia Bogas, Ana Castilla-Plaza, Miguel Bernad-Pineda, Elena Garc?a-Lorenzo, Tamara Rodr?guez-Araya, Alejandro Balsa
doi : 10.1136/annrheumdis-2020-218054
(30 June, 2020)
Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19
Panayiotis G Vlachoyiannopoulos, Eleni Magira, Haris Alexopoulos, Edison Jahaj, Katerina Theophilopoulou, Anastasia Kotanidou, Athanasios G Tzioufas
doi : 10.1136/annrheumdis-2020-218009
(24 June, 2020)
Biologics, spondylitis and COVID-19
James Todd Rosenbaum, Hedley Hamilton, Dongseok Choi, Michael H Weisman, John D Reveille, Kevin L Winthrop
doi : 10.1136/annrheumdis-2020-217941
(10 June, 2020)
Pneumonia vaccination timing in relation to starting conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
Ruth E Costello, Jenny H Humphreys, Kevin L Winthrop, William G Dixon
doi : 10.1136/annrheumdis-2020-217255
(26 June, 2020)
On using machine learning algorithms to define clinically meaningful patient subgroups
Rachel Knevel, Tom WJ Huizinga
doi : 10.1136/annrheumdis-2019-215959
(11 July, 2019)
Response to: ‘On using machine learning algorithms to define clinically meaningful patient subgroups’ by Knevel and Huizinga
Alain Meyer, Lionel Spielmann, François Séverac
doi : 10.1136/annrheumdis-2019-215989
(17 August, 2019)
Association between proton pump inhibitors therapy and fracture risk in patients with rheumatoid arthritis
Shih-Wei Lai, Yu-Hung Kuo, Kuan-Fu Liao
doi : 10.1136/annrheumdis-2019-215982
(12 July, 2019)
Response to: ‘Association between proton pump inhibitors therapy and fracture risk in patients with rheumatoid arthritis’ by Lai et al
Gulsen Ozen, Kaleb Michaud
doi : 10.1136/annrheumdis-2019-215992
(12 August, 2019)
Performance of the systemic lupus erythematosus disease activity score (SLE-DAS) in a Latin American population.
Melissa G Rodr?guez-Gonz?lez, Grissell A Valero-Gaona, Tania Vargas-Aguirre, Luis M Amezcua Guerra
doi : 10.1136/annrheumdis-2019-216028
(29 July, 2019)
Response to: ‘Performance of the systemic lupus erythematosus disease activity score (SLE-DAS) in a Latin American population’ by Rodr?guez-Gonz?lez et al
Diogo Jesus, Ana Matos, Carla Henriques, Margherita Zen, Andrea Doria, Lu?s Sousa Inês
doi : 10.1136/annrheumdis-2019-216110
(7 August, 2019)
Ultrasonographic salivary gland evaluation in systemic sclerosis: is sicca syndrome secondary to an authentic overlap syndrome or another specific fibrotic manifestation of the disease?
Guillaume Coiffier, Sandrine Jousse-Joulin, Divi Cornec, Ronan Garlantézec, Aurore Bleuzen, Elisabeth Diot, Patrick Jego, Alice Ballerie, Alain Lescoat
doi : 10.1136/annrheumdis-2019-215972
(12 July, 2019)
Response to: ‘Ultrasonographic salivary gland evaluation in systemic sclerosis: is sicca syndrome secondary to an authentic overlap syndrome or another specific fibrotic manifestation of the disease?’ by Coiffier et al
Marion Couderc, Jean-Jacques Dubost
doi : 10.1136/annrheumdis-2019-215991
(7 August, 2019)
ugmented versus artificial intelligence for stratification of patients with myositis
Michael Mahler, Brenden Rossin, Olga Kubassova
doi : 10.1136/annrheumdis-2019-216000
(30 July, 2019)
Response to ‘Augmented vs. artificial intelligence for stratification of patients with myositis’ by Mahler et al
Alain Meyer, Lionel Spielmann, François Séverac
doi : 10.1136/annrheumdis-2019-216014
(30 July, 2019)
How to communicate in science
Lars Klareskog, Anca Irinel Catrina, Camilla Svensson, Vivianne Malmstrom
doi : 10.1136/annrheumdis-2019-216016
(13 August, 2019)
Response to: “How to communicate in science” by Klareskog et al
René Toes, David S Pisetsky
doi : 10.1136/annrheumdis-2019-216045
(13 August, 2019)
Effectiveness of influenza vaccine in TNF inhibitors treated patients: comment on the article by Burmester et al
Giovanni Adami, Angelo Fassio, Giovanni Orsolini, Alessandro Giollo, Davide Gatti, Maurizio Rossini
doi : 10.1136/annrheumdis-2019-215174
(20 February, 2019)
Is retinal microvascular damage an early manifestation of systemic sclerosis?
Florenzo Iannone, Cinzia Rotondo
doi : 10.1136/annrheumdis-2019-215127
(9 February, 2019)
